It’s only fair to share… Lomonitinib CAS 2923221-56-9 MF C27H24N4O2 MW436.5 g/mol 3-(3,4-dimethoxyphenyl)-1-(1,2,3,4-tetrahydroisoquinolin-7-yl)pyrazolo[4,5-c]quinoline 3-(3,4-dimethoxyphenyl)-1-(1,2,3,4-tetrahydroisoquinolin-7-yl)-1H-pyrazolo[4,3-c]quinolinetyrosine kinase inhibitor, antineoplastic, ZE46-0134, Eilean Therapeutics, U4DPU7W7QU Lomonitinib (also known as ZE46-0134) is a highly potent, selective, orally bioavailable pan-FLT3 and IRAK4 small molecule inhibitor being developed for the treatment of Acute Myeloid Leukemia (AML). Developed by Eilean Therapeutics in collaboration with …
Tag «tyrosine kinase inhibitor»
Lasmotinib
It’s only fair to share… Lasmotinib CAS 2127107-15-5 MF C19H19FN4O2S MW386.4 g/mol 3-(carbamoylamino)-5-[2-(3-fluorophenyl)ethynyl]-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamide 3-(carbamoylamino)-5-[(3-fluorophenyl)ethynyl]-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamidetyrosine kinase inhibitor, antineoplastic, PHI-101, PHI 101, U2UY9TBQ8Z Lasmotinib (also known by its research code PHI-101) is a next-generation, orally bioavailable targeted cancer therapy. It functions as a dual FLT3 and CHK2 inhibitor. It is primarily being investigated to treat Acute Myeloid Leukemia …
Birelentinib
It’s only fair to share… Birelentinib CAS 2662512-15-2 MF C23H21F2N5O3 MW453.4 g/mol [(2S,5S)-5-[4-amino-5-[4-(2,3-difluorophenoxy)phenyl]imidazo[5,1-f][1,2,4]triazin-7-yl]oxan-2-yl]methanol [(2S,5S)-5-{4-amino-5-[4-(2,3-difluorophenoxy)phenyl]imidazo[5,1-f][1,2,4]triazin-7-yl}oxan-2-yl]methanoltyrosine kinase inhibitor, antineoplastic, DZD8586, DZD 8586, Fast Track designation, BTK-IN-30, Z2F599L9GD Birelentinib (also known as DZD8586) is a first-in-class, non-covalent dual inhibitor of LYN (lymphocyte-specific protein tyrosine kinase) and BTK (Bruton’s tyrosine kinase). It is currently being developed by Dizal Pharmaceutical as an oral therapy for various B-cell malignancies. Clinical Status …
Veonetinib
It’s only fair to share… Veonetinib 👉CAS 1210828-09-3 MF C27H28FN3O4 MW 477.5 g/mol 5-[2-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxyethyl]-5-azaspiro[2.4]heptan-7-ol 5-AZASPIRO(2.4)HEPTAN-7-OL, 5-(2-((4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-6-METHOXY-7-QUINOLINYL)OXY)ETHYL)- 5-(2-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol (7RS)-5-[2-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin7-yl}oxy)ethyl]-5-azaspiro[2.4]heptan-7-oltyrosine kinase inhibitor, antineoplastic, U7PA8S6XGJ 👉SYN [WO2010021918] https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2010021918&_cid=P21-MN159E-69738-1 Example 3 5-(2-(4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol The above product from Example 2 (75 mg) was dissolved into MeOH (8 ml) and stirred at RT. NaBH4 (75 mg) was added to the reaction and stirred at …
Deulorlatinib
It’s only fair to share… Deulorlatinib CAS 2131126-33-3 MFC21H162H3FN6O2, MW 409.4 g/mol (10R)-7-amino-12-fluoro-2-(2H3)methyl-10,16-dimethyl15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitriletyrosine kinase inhibitor, antineoplastic, 7PW3UT8C9B, TGRX 326, TGRX-326 Deulorlatinib is an orally bioavailable inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1), with potential antineoplastic activity. Upon oral administration, deulorlatinib targets, binds to and inhibits the activity of ALK and …
Soquelitinib
It’s only fair to share… Soquelitinib CAS 2226636-04-8 MF C25H30N4O4S2, 514.7 g/mol N-[5-({4-methoxy-2-methyl-5-[(3R)-3-methyl-4-(prop-2-enoyl)-1,4-diazepane-1-carbonyl]phenyl}sulfanyl)-1,3-thiazol-2-yl]cyclopropane-1-carboxamidetyrosine kinase inhibitor, antineoplastic, CPI818, CPI-000818, CPI596, CP I818, CPI 000818, CP I596, 6I5H17AN3I, N-[5-[4-methoxy-2-methyl-5-[(3R)-3-methyl-4-prop-2-enoyl-1,4-diazepane-1-carbonyl]phenyl]sulfanyl-1,3-thiazol-2-yl]cyclopropanecarboxamide Soquelitinib (CPI-818) is an experimental drug which acts as a selective inhibitor of the enzyme interleukin-2-inducible T-cell kinase (ITK). It is in clinical trials for the treatment of T-cell lymphoma.[1][2] Soquelitinib is an orally available, …
Nefextinib
It’s only fair to share… Nefextinib CAS 2070931-57-4 MF C22H23FN6OS MW 438.52 7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-[1-(piperidin4-yl)-1H-pyrazol-4-yl]thieno[3,2-d]pyrimidin-2-amine 7-(4-FLUORO-2-METHOXYPHENYL)-6-METHYL-N-(1-(PIPERIDIN-4-YL)-1H-PYRAZOL-4-YL) THIENO (3,2-D)PYRIMIDIN-2-AMINEtyrosine kinase inhibitor, antineoplastic, DL772G3NN7, MAX-40279, MAX 40279 Nefextinib is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, nefextinib binds to and inhibits both …
Lunbotinib
It’s only fair to share… Lunbotinib CAS 2479961-46-9 MF C28H28FN11 MW537.6 g/mol 2-[6-(6-{[6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl]methyl}-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl]-6-methyl-N-(5-methyl1H-pyrazol-3-yl)pyrimidin-4-aminetyrosine kinase inhibitor, antineoplastic, KL3T9ZU6HQ Lunbotinib is an orally bioavailable selective inhibitor of the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, lunbotinib selectively binds to various RET fusions and mutations, including solvent front resistance mutations, and inhibits the …